# Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

> **NCT03508739** · PHASE3 · SUSPENDED · sponsor: **University of Pennsylvania** · enrollment: 25 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Pre-diabetic
- Hypertension
- Elevated Blood Pressure

## Interventions

- **DRUG:** Sacubitril/Valsartan 200mg (blinded)
- **DRUG:** Valsartan 160mg (blinded)

## Key facts

- **NCT ID:** NCT03508739
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** We do not have active funding at this time.
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508739, "Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03508739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*